Introduction
Atrial kick is the atrial contraction phase of the cardiac cycle. Contraction of the atria generates a force that propels blood across the mitral and tricuspid valves. This contribution occurs late in atrial systole, when blood flows from the left atrium into the left ventricle. In healthy individuals, atrial kick accounts for 20% to 30% of left ventricular filling. In decompensated heart failure, the atrial kick may be appreciated clinically as the 4th heart sound.[1][2]
Function
Register For Free And Read The Full Article
Search engine and full access to all medical articles
10 free questions in your specialty
Free CME/CE Activities
Free daily question in your email
Save favorite articles to your dashboard
Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Function
Physiological Role of the Atrial Kick and Integration in the Cardiac Cycle
Understanding the physiological significance and clinical implications of the atrial kick requires an examination of the cardiac cycle. This cycle is the complete sequence of myocardial events that includes ventricular filling, isovolumetric contraction, ejection of blood, and myocardial relaxation.
The cardiac cycle is divided into 2 primary phases: diastole and systole. Diastole is the period of ventricular relaxation and filling. Systole is the period of ventricular contraction and ejection. Each phase is further subdivided into periods defined by pressure-volume relationships and valve dynamics.
Phases of Left Ventricular Diastole
Left ventricular diastole occurs in 4 periods: isovolumetric relaxation, early diastolic rapid filling, diastasis, and atrial contraction.[3] Isovolumetric relaxation begins during ventricular systole after the aortic valve closes and the ventricle relaxes, lowering intraventricular pressure without a change in volume. When ventricular pressure falls below left atrial pressure, blood from the left atrium forces open the mitral valve and flows into the left ventricle. Early rapid filling is passive, driven by the pressure gradient, and contributes 70% to 80% of blood transfer during diastole. Continued passive flow across the mitral valve equalizes pressures in the left atrium and left ventricle, halting blood flow. This cessation of flow defines diastasis, which ends with the onset of atrial contraction. The final phase, atrial contraction, is also known as the atrial kick.
The atrial contraction phase is initiated by spontaneous electrical activity from the sinoatrial node located in the right atrium near the opening of the superior vena cava.[4][5][6] Electrical impulses generated by the sinoatrial node spread across the right atrium through 3 internodal pathways: anterior, middle, and posterior. The anterior internodal pathway gives rise to the Bachmann bundle, which transmits electrical activity to the left atrium. Depolarization and subsequent contraction follow the propagation of electrical activity across both atria, driving residual blood through the mitral valve. This phase accounts for 20% to 30% of the total diastolic volume entering the left ventricle.
Issues of Concern
Multiple factors influence blood flow across the mitral valve and the contribution of the atrial kick to left ventricular end-diastolic volume. These factors are either structural, electrophysiological, or physiological in nature.
Structural factors include valvular abnormalities such as mitral or aortic stenosis, as well as left ventricular hypertrophy. In mitral stenosis, the left atrium must generate greater pressure to overcome resistance from a narrowed valve orifice. In left ventricular hypertrophy, the decreased pressure gradient across the mitral valve similarly requires increased atrial force to maintain adequate filling.[7]
Electrophysiological factors include atrial fibrillation, atrial flutter, and abnormalities involving the atrioventricular node, all of which impair coordinated atrial contraction. Physiological factors include conditions such as exercise, pregnancy, and sepsis, which alter hemodynamic demands and modify the relative contribution of the atrial kick to ventricular filling.
Echocardiographic Assessment of Transmitral Velocities: The Role and Importance of the Atrial Kick
Flow across the mitral valve may be measured using transthoracic echocardiography. During the early rapid filling phase of ventricular diastole, peak transmitral velocity is measured with pulse wave Doppler and is referred to as the "E wave." Flow across the mitral valve during atrial contraction, or the atrial kick, is also visualized and measured, producing the "A wave." Both E and A waves are demonstrated on pulse wave Doppler.[8] The E/A ratio is used to evaluate left ventricular diastolic dysfunction. A normal E/A ratio is less than 0.8. Aging and diastolic dysfunction reduce transmitral flow during early rapid filling and enhance flow during atrial contraction, altering the E/A ratio.[9]
Loss of the Atrial Kick
The atrial kick may be absent in medical conditions that impair atrial systole. Atrial muscle fibers contract asynchronously due to multiple or disordered pacemaker foci in atrial fibrillation and atrial flutter. These arrhythmias diminish atrial contraction through 2 mechanisms. First, asynchronous contraction prevents effective atrial systole and limits blood propulsion across the mitral valve. Second, rapid ventricular depolarization shortens diastole, reducing the time available for passive filling. Both mechanisms decrease left ventricular filling and reduce cardiac output.
Loss of the atrial kick may be identified on electrocardiography (ECG) by the absence of regular P waves. The presence of fibrillation waves or the classic sawtooth pattern of atrial flutter indicates the absence of synchronized atrial contraction. In patients with chronic atrial fibrillation and preserved ejection fraction, elevated pulse rates may serve as a compensatory mechanism to counter reduced cardiac output.[10] On echocardiography, diminution of the atrial kick is demonstrated by the absence of the A wave.
In healthy individuals, suppression of the atrial kick may not cause clinical symptoms. However, absence of atrial contraction in the presence of structural, electrophysiological, or physiological cardiac alterations may result in dyspnea on exertion, pulmonary edema, or, in some cases, syncope.
Clinical Conditions with Increased Dependence on the Atrial Kick
The atrial kick plays a disproportionately large role in preserving hemodynamics in certain structural and functional cardiac disorders. Some frequently encountered conditions are explained below.
Mitral stenosis
A stenotic mitral valve reduces the cross-sectional area available for blood flow, thereby limiting transmitral filling. Impaired flow results in residual blood within the left atrium after the early rapid filling phase and increases dependence on the atrial kick to complete left ventricular filling. Shortened diastole caused by physiological factors such as tachycardia or pregnancy, and by pathological factors such as atrial fibrillation or atrial flutter, can precipitate flash pulmonary edema. This presentation often manifests as exertional dyspnea and reduced exercise tolerance. Mitral stenosis was historically regarded as an independent risk factor for atrial fibrillation, although the relationship more accurately reflects an association among atrial fibrillation, mitral stenosis, and rheumatic heart disease.[11]
Aortic stenosis
Aortic stenosis can increase dependence on the atrial kick due to upstream effects of impaired ventricular systolic and diastolic function. Aortic stenosis obstructs left ventricular outflow, leading to an increase in left ventricular end-systolic volume, concentric hypertrophy, and elevated left ventricular end-diastolic pressure.[12][13] The resulting ventricular remodeling produces diastolic dysfunction, which decreases the transmitral pressure gradient and reduces filling during early diastole. These changes are reflected in alterations of the left atrial volume index and the E/e′ ratio, where e′ represents early diastolic mitral annular velocity measured by tissue Doppler. Together, these indices demonstrate increased reliance on atrial contraction for adequate ventricular filling.[14]
Heart failure with preserved ejection fraction
Heart failure with preserved ejection fraction (HFpEF) arises from impaired relaxation of the left ventricle, resulting in diastolic stiffness and loss of compliance. Reduced compliance increases dependence on the atrial kick to preserve end-diastolic volume. Heart failure with preserved ejection fraction is particularly detrimental in patients with concurrent atrial arrhythmias, as the absence of atrial systole eliminates the ability to compensate for reduced compliance. Loss of atrial contraction has been shown to decrease cardiac output by 20% to 30%, a finding of particular significance in diastolic dysfunction. Restoration of sinus rhythm improves forward flow and contractility, as demonstrated by hemodynamic improvement in patients with heart failure managed with rhythm control.[15]
Clinical Significance
Patients who rely on the atrial kick to maintain adequate ventricular filling may experience symptomatic and prognostic benefits from the treatment of atrial arrhythmias. Management of these cardiac disturbances may be achieved through 2 approaches: rate control and rhythm modulation.
Rate stabilization reduces the ventricular response, thereby prolonging diastole and decreasing reliance on the atrial kick. Rhythm correction restores sinus rhythm, reestablishing synchronized atrial contraction and optimizing ventricular filling.[16]
Modalities That Stabilize Cardiac Rate
β-blockers and nondihydropyridine calcium channel blockers are 1st-line agents for rate control. Slowing the ventricular rate increases the duration of diastole, allowing greater passive early diastolic filling. The resulting hemodynamic changes reduce dependence on the atrial kick, improve end-diastolic volume, and augment cardiac output. Pharmacological rate regulation is the preferred strategy in asymptomatic adults older than 80 years with low cardiovascular risk.[17]
Atrioventricular nodal ablation with pacemaker implantation is reserved for patients with ventricular responses refractory to pharmacological rate and rhythm modulation or recurrent atrial tachyarrhythmias despite catheter ablation. This approach is used sparingly due to its invasive nature and the induction of ventricular dyssynchrony from right ventricular pacing, which may necessitate additional interventions to address pacing-induced dyssynchrony.[18][19]
Therapies That Regulate Rhythm
Rhythm control is the preferred strategy for restoring sinus rhythm in patients who are symptomatic or have elevated cardiovascular risk.[20][21] Rhythm restoration synchronizes atrial and ventricular contraction, thereby optimizing ventricular filling and improving cardiac output.
Cardioversion
Direct cardioversion is often the initial approach to achieve rhythm regulation. Some patients do not respond to this modality, while others experience recurrence of atrial fibrillation or atrial flutter following initial conversion to sinus rhythm. Long-term management depends on symptom burden and cardiovascular risk.
Patients with low symptom burden and low cardiovascular risk are generally treated with rate-modulating agents and anticoagulation, whereas younger patients with significant symptom burden or high cardiovascular risk are offered catheter ablation or pharmacological rhythm-regulating therapy. Anticoagulation must be established before cardioversion, or transesophageal echocardiography must confirm the absence of thrombus in the left atrial appendage, as restoration of sinus rhythm can dislodge atrial thrombi and precipitate arterial thromboembolism.[22][23]
Pharmacological treatment
Pharmacological rhythm control may be achieved with several antiarrhythmic agents. The presence or absence of structural heart disease largely guides selection. Flecainide, dofetilide, propafenone, dronedarone, amiodarone, and sotalol are generally preferred in patients without structural abnormalities.[24][25] Propafenone and flecainide are avoided in the presence of structural heart disease because of the increased risk of ventricular tachycardia and other malignant arrhythmias, including torsade de pointes. Sotalol, dronedarone, dofetilide, and amiodarone are appropriate options for patients with structural heart disease but preserved systolic function. Amiodarone and dronedarone are the primary pharmacological choices for patients with heart failure.[26]
Catheter ablation
In younger patients without structural heart disease, catheter ablation may be offered as 1st-line therapy for paroxysmal atrial fibrillation because it provides lower recurrence rates with comparable adverse event rates.[27][28] Radiofrequency ablation achieves rhythm regulation by electrically isolating the pulmonary veins, which account for approximately 90% of ectopic foci.[29] The procedure preserves the sinus node as the primary pacemaker to maintain atrioventricular synchrony. Reported 1-year success rates at high-volume centers range from 60% to 80%.[30]
Surgical maze procedures
Surgical maze procedures may be considered in patients undergoing cardiac surgery for other indications. These procedures involve the creation of atrial scar tissue using various techniques. Electrically inert scar tissue interrupts abnormal conduction circuits, reducing the likelihood of nonsinus atrial arrhythmias.[31]
Other Issues
Available therapeutic strategies can restore sinus rhythm and reestablish atrial function. Despite these advances, limited evidence exists regarding the mechanisms underlying the recurrence of atrial fibrillation and the incomplete recovery of the atrial kick following rhythm conversion. Future research should focus on identifying structural and electrophysiological predictors of recurrence and clarifying the determinants of atrial mechanical recovery.
Enhancing Healthcare Team Outcomes
The atrial kick is an essential component of the cardiac cycle, as it contributes to maximizing left ventricular end-diastolic volume. Recognition of its absence is clinically important, and identification of the underlying etiology should guide further evaluation. Restoration of sinus rhythm, ideally in consultation with cardiologists or cardiac electrophysiologists, is the primary therapeutic objective when feasible.
References
Namana V, Gupta SS, Sabharwal N, Hollander G. Clinical significance of atrial kick. QJM : monthly journal of the Association of Physicians. 2018 Aug 1:111(8):569-570. doi: 10.1093/qjmed/hcy088. Epub [PubMed PMID: 29750254]
Batul SA, Gopinathannair R. Atrial Fibrillation in Heart Failure: a Therapeutic Challenge of Our Times. Korean circulation journal. 2017 Sep:47(5):644-662. doi: 10.4070/kcj.2017.0040. Epub 2017 Aug 22 [PubMed PMID: 28955382]
Schiros CG, Ahmed MI, McGiffin DC, Zhang X, Lloyd SG, Aban I, Denney TS Jr, Dell'Italia LJ, Gupta H. Mitral Annular Kinetics, Left Atrial, and Left Ventricular Diastolic Function Post Mitral Valve Repair in Degenerative Mitral Regurgitation. Frontiers in cardiovascular medicine. 2015:2():31. doi: 10.3389/fcvm.2015.00031. Epub 2015 Aug 17 [PubMed PMID: 26664902]
Keith A, Flack M. The Form and Nature of the Muscular Connections between the Primary Divisions of the Vertebrate Heart. Journal of anatomy and physiology. 1907 Apr:41(Pt 3):172-89 [PubMed PMID: 17232727]
Restrepo AJ, Razminia M, Sánchez-Quintana D, Cabrera JÁ. Myoarchitecture of the Sinoatrial Node and its Relevance for Catheter Ablation: Anatomy and Histology. JACC. Case reports. 2024 Jan 17:29(2):102153. doi: 10.1016/j.jaccas.2023.102153. Epub 2023 Dec 8 [PubMed PMID: 38264311]
Level 3 (low-level) evidenceKashou AH,Basit H,Chhabra L, Physiology, Sinoatrial Node (SA Node) 2020 Jan; [PubMed PMID: 29083608]
Kono T, Sabbah HN, Rosman H, Alam M, Stein PD, Goldstein S. Left atrial contribution to ventricular filling during the course of evolving heart failure. Circulation. 1992 Oct:86(4):1317-22 [PubMed PMID: 1394938]
Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Popescu BA, Waggoner AD. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography. 2016 Apr:29(4):277-314. doi: 10.1016/j.echo.2016.01.011. Epub [PubMed PMID: 27037982]
Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003 Jan 8:289(2):194-202 [PubMed PMID: 12517230]
Mori K, Goto T, Yamamoto J, Muto K, Kikuchi S, Wakami K, Fukuta H, Ohte N. Compensatory Increase in Heart Rate Is Responsible for Exercise Tolerance among Male Patients with Permanent Atrial Fibrillation. The Tohoku journal of experimental medicine. 2018 Dec:246(4):265-274. doi: 10.1620/tjem.246.265. Epub [PubMed PMID: 30568108]
Probst P, Goldschlager N, Selzer A. Left atrial size and atrial fibrillation in mitral stenosis. Factors influencing their relationship. Circulation. 1973 Dec:48(6):1282-7 [PubMed PMID: 4271625]
Hein S, Arnon E, Kostin S, Schönburg M, Elsässer A, Polyakova V, Bauer EP, Klövekorn WP, Schaper J. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation. 2003 Feb 25:107(7):984-91 [PubMed PMID: 12600911]
Badiani S, van Zalen J, Treibel TA, Bhattacharyya S, Moon JC, Lloyd G. Aortic Stenosis, a Left Ventricular Disease: Insights from Advanced Imaging. Current cardiology reports. 2016 Aug:18(8):80. doi: 10.1007/s11886-016-0753-6. Epub [PubMed PMID: 27384950]
Laenens D, Stassen J, Galloo X, Ewe SH, Singh GK, Ammanullah MR, Hirasawa K, Sia CH, Butcher SC, Chew NWS, Kong WKF, Poh KK, Ding ZP, Ajmone Marsan N, Bax JJ. The impact of atrial fibrillation on prognosis in aortic stenosis. European heart journal. Quality of care & clinical outcomes. 2023 Dec 22:9(8):778-784. doi: 10.1093/ehjqcco/qcad004. Epub [PubMed PMID: 36669758]
Level 2 (mid-level) evidenceKoizumi R, Funamoto K, Hayase T, Kanke Y, Shibata M, Shiraishi Y, Yambe T. Numerical analysis of hemodynamic changes in the left atrium due to atrial fibrillation. Journal of biomechanics. 2015 Feb 5:48(3):472-8. doi: 10.1016/j.jbiomech.2014.12.025. Epub 2014 Dec 16 [PubMed PMID: 25547024]
Cain ME. Normal sinus rhythm without the normal atrial kick. Heart rhythm. 2005 Sep:2(9):929-30 [PubMed PMID: 16171745]
Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 9:285(18):2370-5 [PubMed PMID: 11343485]
Level 2 (mid-level) evidenceVernooy K, Dijkman B, Cheriex EC, Prinzen FW, Crijns HJ. Ventricular remodeling during long-term right ventricular pacing following His bundle ablation. The American journal of cardiology. 2006 Apr 15:97(8):1223-7 [PubMed PMID: 16616030]
Tops LF, Schalij MJ, Holman ER, van Erven L, van der Wall EE, Bax JJ. Right ventricular pacing can induce ventricular dyssynchrony in patients with atrial fibrillation after atrioventricular node ablation. Journal of the American College of Cardiology. 2006 Oct 17:48(8):1642-8 [PubMed PMID: 17045901]
Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, Fetsch T, van Gelder IC, Haase D, Haegeli LM, Hamann F, Heidbüchel H, Hindricks G, Kautzner J, Kuck KH, Mont L, Ng GA, Rekosz J, Schoen N, Schotten U, Suling A, Taggeselle J, Themistoclakis S, Vettorazzi E, Vardas P, Wegscheider K, Willems S, Crijns HJGM, Breithardt G, EAST-AFNET 4 Trial Investigators. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. The New England journal of medicine. 2020 Oct 1:383(14):1305-1316. doi: 10.1056/NEJMoa2019422. Epub 2020 Aug 29 [PubMed PMID: 32865375]
Willems S, Borof K, Brandes A, Breithardt G, Camm AJ, Crijns HJGM, Eckardt L, Gessler N, Goette A, Haegeli LM, Heidbuchel H, Kautzner J, Ng GA, Schnabel RB, Suling A, Szumowski L, Themistoclakis S, Vardas P, van Gelder IC, Wegscheider K, Kirchhof P. Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. European heart journal. 2022 Mar 21:43(12):1219-1230. doi: 10.1093/eurheartj/ehab593. Epub [PubMed PMID: 34447995]
Level 1 (high-level) evidenceDurmaz E, Karpuz MH, Bilgehan K, Ikitimur B, Ozmen E, Ebren C, Polat F, Koca D, Tokdil KO, Kandemirli SG, Atici A, Ongen Z. Left atrial thrombus in patients with atrial fibrillation and under oral anticoagulant therapy; 3-D transesophageal echocardiographic study. The international journal of cardiovascular imaging. 2020 Jun:36(6):1097-1103. doi: 10.1007/s10554-020-01811-x. Epub 2020 Mar 5 [PubMed PMID: 32140812]
Kozieł M, Merino JL, De Caterina R, Huber K, Jin J, Melino M, Goette A, Lip GYH, ENSURE-AF Investigators. Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSURE-AF trial. European journal of clinical investigation. 2020 May:50(5):e13221. doi: 10.1111/eci.13221. Epub 2020 Mar 30 [PubMed PMID: 32150758]
Ferguson JJ. Meeting highlights. Highlights of the 71st scientific sessions of the American Heart Association. Circulation. 1999 May 18:99(19):2486-91 [PubMed PMID: 10330376]
Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH, EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. The New England journal of medicine. 2007 Sep 6:357(10):987-99 [PubMed PMID: 17804843]
AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. Journal of the American College of Cardiology. 2003 Jul 2:42(1):20-9 [PubMed PMID: 12849654]
Imberti JF, Ding WY, Kotalczyk A, Zhang J, Boriani G, Lip G, Andrade J, Gupta D. Catheter ablation as first-line treatment for paroxysmal atrial fibrillation: a systematic review and meta-analysis. Heart (British Cardiac Society). 2021 Oct:107(20):1630-1636. doi: 10.1136/heartjnl-2021-319496. Epub 2021 Jul 14 [PubMed PMID: 34261737]
Level 1 (high-level) evidenceWazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W, Bash D, Schweikert R, Brachmann J, Gunther J, Gutleben K, Pisano E, Potenza D, Fanelli R, Raviele A, Themistoclakis S, Rossillo A, Bonso A, Natale A. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA. 2005 Jun 1:293(21):2634-40 [PubMed PMID: 15928285]
Level 1 (high-level) evidenceLee G, Spence S, Teh A, Goldblatt J, Larobina M, Atkinson V, Brown R, Morton JB, Sanders P, Kistler PM, Kalman JM. High-density epicardial mapping of the pulmonary vein-left atrial junction in humans: insights into mechanisms of pulmonary vein arrhythmogenesis. Heart rhythm. 2012 Feb:9(2):258-64. doi: 10.1016/j.hrthm.2011.09.010. Epub 2011 Sep 9 [PubMed PMID: 21907170]
Lohrmann G, Kaplan R, Ziegler PD, Monteiro J, Passman R. Atrial fibrillation ablation success defined by duration of recurrence on cardiac implantable electronic devices. Journal of cardiovascular electrophysiology. 2020 Dec:31(12):3124-3131. doi: 10.1111/jce.14781. Epub 2020 Oct 27 [PubMed PMID: 33079437]
Loardi C, Alamanni F, Galli C, Naliato M, Veglia F, Zanobini M, Pepi M. Surgical Treatment of Concomitant Atrial Fibrillation: Focus onto Atrial Contractility. BioMed research international. 2015:2015():274817. doi: 10.1155/2015/274817. Epub 2015 Jul 1 [PubMed PMID: 26229956]